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Abstract
Background: Lung cancer is a leading cause of cancer morbidity. To improve an understanding of molecular causes of
disease a transgenic mouse model was investigated where targeted expression of the serine threonine kinase c-Raf to
respiratory epithelium induced initialy dysplasia and subsequently adenocarcinomas. This enables dissection of genetic
events associated with precancerous and cancerous lesions.
Methodology/Principal Findings: By laser microdissection cancer cell populations were harvested and subjected to whole
genome expression analyses. Overall 473 and 541 genes were significantly regulated, when cancer versus transgenic and
non-transgenic cells were compared, giving rise to three distinct and one common regulatory gene network. At advanced
stages of tumor growth predominately repression of gene expression was observed, but genes previously shown to be up-
regulated in dysplasia were also up-regulated in solid tumors. Regulation of developmental programs as well as epithelial
mesenchymal and mesenchymal endothelial transition was a hall mark of adenocarcinomas. Additionaly, genes coding for
cell adhesion, i.e. the integrins and the tight and gap junction proteins were repressed, whereas ligands for receptor
tyrosine kinase such as epi- and amphiregulin were up-regulated. Notably, Vegfr- 2 and its ligand Vegfd, as well as Notch
and Wnt signalling cascades were regulated as were glycosylases that influence cellular recognition. Other regulated
signalling molecules included guanine exchange factors that play a role in an activation of the MAP kinases while several
tumor suppressors i.e. Mcc, Hey1, Fat3, Armcx1 and Reck were significantly repressed. Finally, probable molecular switches
forcing dysplastic cells into malignantly transformed cells could be identified.
Conclusions/Significance: This study provides insight into molecular pertubations allowing dysplasia to progress further to
adenocarcinoma induced by exaggerted c-Raf kinase activity.
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Introduction
The leading cause for lung cancer is cigarette smoking. More
than 80% of lung cancer patients either actively smoke or have been
smoking in the past even though other factors such as exposure to
asbestos, radon, and genetic factors may contribute to disease as
well. Notably, at thetimeof diagnosisabout one thirdof thepatients
are already in an advanced stage IV of disease therefore limiting
curative therapeutic options, while 15–20% of patients exhibit signs
of disease at an early stage. Tumors are classified by morphological
appearance and are divided into small cell (SCLC) and non-small
cell lung cancer (NSCLC), with NSCLC accounting for approxi-
mately 75–80% of all lung cancers. This group is divided further
into squamous cell (35–40%) and adenocarcinomas (30–40%),
where as the large cell and the undifferentiated non-small cell lung
cancers account for the remaining subtypes [1].
Despite intensive research the molecular events essential for the
development of lung adenocarcinomas remain elusive, even
though it is well established, that the disease involves activation
of oncogenes. For instance, K-ras mutations are detected in 20–
30% of adenocarcinomas and inactivation of tumor suppressor
genes, such as p53, p16INK4a, and Rb are frequently observed as
well [2,3,4,5]. Defects in DNA repair pathways and cell cycle
checkpoints allow tumor cells to accumulate mutations that are
advantageous to growth, invasion, and spread. Of considerable
importance is the abnormal expression of growth factors, their
receptors, and their signalling pathways that may result in
unrestrained cell division. For instance, the transmembrane
receptor EGFR (epidermal growth factor receptor) is expressed
at high levels in adenocarcinomas [6]. EGFR and its ligands, the
neuregulins initiate a signal transduction cascade involving the
mitogen-activated protein kinase pathway that constitutes a
growth stimulatory loop in lung cancer [7]. Additionaly, high
telomerase activity was reported for primary NSCLC particularly
at advanced stages of disease while in normal quiescent cells
telomerase activity is not detectable. There is a need to better
PLoS ONE | www.plosone.org 1 October 2009 | Volume 4 | Issue 10 | e7315understand the molecular basis of tumorigensis and microarray
studies are instrumental in the decoding of the lung cancer genom.
Recently, we reported the molecular characterisation of lung
dysplasia in a c-Raf transgenic mouse model that develops lung
adenocarcinomas [8,9]. Specifically, c-Raf is a serine/threonine
proteine kinase and a direct downstream effector of Ras. It is
activated to its GTP-bound state in response to various ligands
through binding to their cognate receptors, and is involved in
several signaling cascades. Undue activation of Raf signalling is a
key event in lung adenocarcinoma and this mouse model
recapitulates the genetic events associated with the different stages
of tumor development, i.e. from low to high grade dysplasia to
highly and less differentiated adenocarcinomas. There is also
evidence for Raf-1 overexpression in human lung adenocarcino-
mas [10] and in a recent report c-Raf was shown to antagonize
apoptosis induced by IFNa in human lung cancer cells [11,12].
In our recent study we focused particularly on the regulatory gene
n e t w o r k sa s s o c i a t e dw i t hd y s p l a s i aa n di d e n t i f i e ds o m em o l e c u l a r
reactions that were consider as priming factors for malignant
transformation. We now report findings of approximately 12 month
old transgenic mice to gain further information at advanced stages of
disease, i.e. beyond dysplasia. By use of laser microdissection pressure
catapulting (LMPC) tumor cells without any contamination with
normal epithelia, blood vessels, stromal cellsand tumor necrosiscould
be isolated. Genome wide expression analyses of tumor lesions were
than compared with transgenic but otherwise normal cells or non-
transgenic cells. We combined microdissection with gene expression
profiling to determine differentially expressed genes as to identify the
gene regulatory networks associated with adenocarcinoma. We
identified groups of genes acting in concert that were specifically
associatedwithmalignanttransformationandweidentifiedcandidate
genes and pathways that likely contribute to progression from lung
dysplasia to cancer. Overall, this study identified several regulatory
gene networks specifically associated with the progression from
dysplasia to malignantly transformed respiratory epithelium.
Results
Histological changes
As shwon in Figure 1, twelve month old animals display
multifocal tumor growth and typical features of lung adenocarci-
nomas. The morphological abnormalities relate to cell structure,
number of cells, and cytological appearance of the epithelium.
Specifically, the typical bronchioloar columnar epithelium with
vertically oriented nucleus is replaced by tumor cells. The tumors
cells are columnar to polygonal with high nuclear to cytoplasmic
ratios, marked pleomorphism, and prominent nucleoli. Abundant
mitotic activity but also tumor associated apoptosis is observed.
SAM (Significance Analysis of Microarrays)
When transgenic but otherwise unaltered lung cells were
compared with cancer cells a total of 473 significantly regulated
genes (48 up-regulated and 425 down-regulated) were determined
(Supplementary Table S1). In a further comparison of non-
transgenic lung cells with cancer cells 113 up-regulated and 428
down-regulated genes could be identified (Supplementary Table
S2). For such comparison, we requested at least 2-fold differen-
tially expressed genes at an estimated false discovery rate =0.001
(Table 1). Transgenicity alone was associated with 16 up-regulated
and 2 down-regulated genes (Supplementary Table S3). We
further searched for differentially expressed genes by comparing
the data sets of adenocarcinoma vs transgenic and adenocarcino-
ma vs non-transgenic. In such a comparison 426 genes were
regulated in common (Figure 2).
Principal component analysis (PCA) and hierarchical gene
cluster analysis (HCA)
The expression levels were analyzed by GCOS (GeneChip
Operating Software) and the ArrayTrack software. We initial
examined the data in a 34.000 genes 615 samples matrix. The
PCA segregated the data into 3 major groups, namely non-
transgenic, transgenic and adenocarcinoma (Figure 3).
We also performed hierarchical gene cluster analyses and
searched for the closest pair of expression values of 3246
differentially expressed genes that grouped together. Consequently
the data are organized in a phylogenetic tree in which the branch
lengths represent the degree of similarity between the values. A
clear segregation of the analyzed data (adenocarcinoma, trans-
genic but unchanged lung tissue and non-transgenic lung tissue)
was obtained (Figure 4) and the PCA and HCA grouped data
according to their biological state. Correspondingly, gene
expression data of transgenic SP-C/c-Raf lung were well separated
Figure 1. Histological analyses of lung tissue from 12-month-old transgenic mice. Histological analyses of lung tissue from mice transgenic
for lung-targeted expression of the cRaf-1 protein. Lung tissue from a 12-month-old SP-C-c-Raf mouse were sectioned at 10 mm, fixed in methanol/
acetig acid and stained with H&E. We detected multiple foci of adenocarcinoma. A: Overview presentation (magnification: 650), B: adenocarcinoma
(magnification: 6200).
doi:10.1371/journal.pone.0007315.g001
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large difference between these groups. Stringent cut-offs were
used. With an estimated false discovery rate of 0.1 we obtained in
adenocarcinoma 2727 significantly regulated genes (895 up-
regulated and 1832 down-regulated) compared with transgenic
but unaltered cells and 3765 genes (1401 up-regulated and 2364
down-regulated) in adenocarcinoma versus non-transgenic cells.
Comparison of these data sets resulted in 2631 genes regulated in
common in adenocarcinoma (data not shown).
Pathway analysis of significantly expressed genes
The Ingenuity Pathways Analysis (IPA) software was employed
and over 75% of regulated genes were mapped to different
networks in the IPA database. These networks describe functional
relationships among gene products based on findings presented in
peer-reviewed scientifically validated biological pathways. Taken
collectively, 24 and 30 networks could be defined for the
comparison adenocarcinoma vs transgenic and adenocarcinoma
vs non-transgenic cells. Based on pathway analysis the top 4
networks reached a score of 40 or higher and contained 20 or
more genes in each of the networks in the comparison
adenocarcinoma vs transgenic cells (Figure 5 and 6) and in
adenocarcinoma vs non-transgenic cells (Figure 7 and 8). This
demonstrates the extensive relationship and interaction between
the significantly regulated genes in lung cancer. The networks
were specifically associated with cell signalling, cell adhesion,
proliferation and growth, development and lipid metabolism
(Supplementary Figure S1 and S2). In the following, we wish to
describe prominent examples.
Aberrant cell signalling
We searched for genes involved in cell signalling and found 6
genes to be up-regulated in adenocarcinoma ranging between 5.9
to 28.1-fold as well as 36 genes to be down-regulated ranging
between 23.8 to 229.4-fold when transgenic but morphologically
unaltered lung tissue was compared. Likewise 5 genes were up-
regulated between 7.4 to 30.0-fold and 42 genes were down-
regulated (24.1 to 235.2-fold) when compared with non-
transgenic lung tissue. In particular, Pthlh (parathyroid hor-
mone-like hormone protein) was 28.1-fold up-regulated and was
Table 1. Differentially expressed genes (FDR=0.001, FC
#2$).
non-transgenic transgenic tumor
non-transgenic 01 8 5 4 1
transgenic 18 0 473
tumor 541 473 0
doi:10.1371/journal.pone.0007315.t001
Figure 3. Principal component analysis for gene expression
profiles of transformed cells. Principal component analysis of
cancer cells from transgenic SP-C/c-raf mouse model in comparison to
unaltered lung tissue of transgenic and non-transgenic mice. red,
tumor; blue, transgenic non-tumor sample; green, non-transgenic
samples.
doi:10.1371/journal.pone.0007315.g003
Figure 2. Venn diagram for significantly regulated genes. Venn diagram for significantly differential expressed genes. Comparison of tumor
and transgenic unaltered lung tissue with non-transgenic samples. 426 genes were found in tumor, respectively, which were at least 2-fold
differentially expressed (FDR=0.001).
doi:10.1371/journal.pone.0007315.g002
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malignancy [13], but recent studies have revealed its growth-
regulatory effects [14]. Next to its important regulatory effects on
calcium, it is a growth factor for malignant cell lines of many
tissues, including those of the bone, kidney and prostate
[15,16,17]. Importantly, exaggerated Pthlh production is fre-
quently observed in lung carcinoma cell lines and was found to be
overexpressed in all types of lung carcinoma [18,19]. In contrast,
among the down-regulated genes several code for guanine
nucleotide exchange factors (GEFs). In general GEFs stimulate
the dissociation and exchange of bound GDP (guanosine
diphosphate) for GTP (guanosine triphosphat) on Ras in response
to upstream stimuli. Thus, binding of GTP activates RAS proteins.
In adenocarcinoma RasGRP2 is 29.3-fold down-regulated and a
similar 29.9-fold down-regulation was determined in a compar-
ison with non-transgenic cells. Notably, RasGRP2 is targeted to
the plasma membrane by a combination of N-terminal myristoy-
lation and palmitoylation [20]. We found RasGRP3 25.4-fold
down-regulated in adenocarcinoma when compared with trans-
genic but otherwise unaltered cells and 26.9-fold down-regulated
in a comparison with non-transgenic cells. Unlike the down-
regulated GEFs, we found RasGRF1 (RAS protein-specific
Figure 4. Result of the hierarchical cluster analysis. The normalized data were used for the Ward’s Minimum Variance linkage clustering
algorithm. A total of 3246 differentially expressed genes (mean channel intensity .100, FDR: 0.1, Bad Flags: 5) were used in the cluster dendogram to
obtain a clear segregation of the analyzed groups (tumor, transgenic and non-transgenic). Expression values were colour coded with a red green
scale. Green, transcript levels below the median; black, equal to the median and red, greater than median.
doi:10.1371/journal.pone.0007315.g004
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adenocarcinoma as compared with transgenic and 25.4-fold in the
comparison adenocarcinoma vs non-transgenic. Specifically,
RasGRF1 is a calcium-stimulated exchange factor for Ras and
Rac. Additionally, RasGRF1 is a substrate of the tyrosine kinase
Src and it seems that oligomerization of RasGRFs is required for
its biological functions [21].
Surprisingly, the Ras GTPase-activating proteins (RasGAPs) are
not regulated in lung adenocarcinoma. Although both the
RasGEFs and RasGAPs proteins are needed to complete a full
GTPase cycle and to allow for a switch between an inactive and
active state of Ras, the activation state of these Ras proteins, but
not the level of expression, might determine the cellular effects.
Additionally, we found down-regulated Rho guanine nucleotide
exchange factors such as ArhGEF15 (Rho guanine nucleotide
exchange factor 15) (29.4-fold adenocarcinoma vs transgenic/
210.7-fold adenocarcinoma vs non-transgenic), ArhGEF10 (Rho
guanine nucleotide exchange factor 10) (25.1-fold adenocarcino-
ma vs transgenic/26.3-fold adenocarcinoma vs non-transgenic)
and the Rho GTPase activating protein, ArhGAP20 (Rho GTPase
activating protein 20) (26.0-fold adenocarcinoma vs transgenic/
28.5-fold adenocarcinoma vs non-transgenic) to be repressed.
Like Ras proteins, these Rho proteins are activated via
extracellular signals that cause binding and hydrolysis of GTP
and induction of downstream effector molecules [22].
Next tothemembersoftheGEFfamilyweobservedregulation of
molecules in the Wnt signalling pathway. Indeed, Wnt proteins
comprise a family of secreted glycoproteins that play diverse roles in
development, cell proliferation, cell polarity and cell fate determi-
nation [23,24]. Binding of wnt molecules at frizzled transmembrane
receptors stimulates an activation of the Wnt signal pathway. By
activation of the canonical Wnt signal pathway the formation of the
axin of mediated degradation complex is inhibited and cytosolic b-
catenin is stabilized. As a consequence b-catenin enriches itself in
Figure 5. Ingenuity networks: adenocarcinoma versus transgenic mice. Ingenuity networks generated by mapping the focus genes that were
differentially expressed between tumor and transgenic unaltered lung tissue (part I). Each network is graphically displayed with genes/gene products as
nodes (different shapes represent the functional classes of the gene products) and the biological relationships between the nodes as edges (lines). The
length of an edge reflects the evidence in the literature supporting that node-to-node relationship. The intensity of the node color indicates the degree
of up- (red) or downregulation (green) of the respective gene. A solid line without arrow indicates protein-protein interaction. Arrows indicate the
direction of action (either with or without binding) of one gene to another. IPA networks were generated as follows: Upon uploading of genes and
corresponding fold-change expression values (done separately for tumor vs transgenic and tumor vs non-transgenic differentially expressed genes),
each geneidentifier wasmappedtoits correspondinggeneobjectin theIPAKnowledgeBase (partof the IPAalgorithm). Fold-changeexpression values
were used to signedgeneswhose expression was differentially regulated; these ‘‘focus genes’’ were overlaid onto a global molecular network contained
in the IPA Knowledge Base. Networks of these focus genes were thenalgorithmically generated based on their connectivity andscoredaccordingto the
number of focus genes within the network as well as according to the strength of their associations.
doi:10.1371/journal.pone.0007315.g005
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family.WeobservedWnt2(wingless-relatedMMTV integration site
2) to be 213.8-fold repressed in cancer and -16.2-fold down
regulated when compared tonon-transgeniccells.Importantly,Wnt
genes play a role as mediators of epithelial-mesenchymal interac-
tions in the developing lung. It has been shown that Wnt2 is
predominantly expressed in the mesenchyme during the lung
development [25]. Evidence suggests that the Wnt signal pathway is
required for the specification and differentiation of lung epithelial
cells [26,27] and plays a role in lung cancer [28,29]. Nonetheless,
alterations in the Wnt signal pathway in lung cancer are still unclear
and are rather controversial. For example, it has been reported that
immunohistochemical positive staining of b-catenin in the nucleus
was observed in less than 10% of the primary non-small cell lung
adenocarcinomas and was associated with better prognosis [30]. In
contrast, reports suggest components of the Wnt signal pathway in
metastatic lung cancer to be induced [27]. Moreover, in the non-
small cell lung cancer cell line H292, b- catenin as well as further
genes of the Wnt signal pathway were up-regulated [31]. Likewise,
an up-regulation of Wnt5a was observed in lung carcinoma and
discussed in connection with tumor progression [32]. Unlike our
results, Wnt2 was reported to be increased in human non-small cell
lung cancer tissues [33]. We also observed repression of Tcf21. This
protein belongs to the family of basic helix-loop-helix transcription
factors and was 217.7-fold down regulated in cancer compared to
transgenic and 220.8-fold compared to non-transgenic. Tcf21 is
known to forster differentiation of epithelial cells adjacent to
mesenchymal and is a critical molecule for lung development [34].
In fact frequent promoter hypermethylation of Tcf21 was reported
in primary lung adenocarcinomas [35].
Besides altered Wnt signaling molecules we found Notch
pathway to be regulated as well. Notch 4 was 26.8-fold down
regulated in adenocarcinoma compared to transgenic and 27.6-
fold down regulated in the comparison adenocarcinoma versus
non-transgenic. Specifically, Notch 4 (Notch gene homolog 4), a
member of the transmembrane Notch family of receptors is
expressed primarily in embryonic endothelium and in adult
endothelium [36]. Upon binding of its ligand, Delta4, this receptor
becomes activated. When activated, the intracellular subunit
translocates into the nuclei and regulates transcription of many
genes and regulates, among others, vascular endothelial cell
growth factor (VEGF), NFkB and Hes-1 [37,38]. Activation of
Notch signalling plays important roles in development and
maintenance of neoplastic phenotypes [39,40,41].
Remodelling of cell adhesion
We found Chl1 (cell adhesion molecule with homology to
L1CAM) a member of the L1 gene family of neural cell adhesion
Figure 6. Ingenuity networks: adenocarcinoma versus transgenic mice. Ingenuity networks generated by mapping the focus genes that
were differentially expressed between tumor and transgenic unaltered lung tissue (part II).
doi:10.1371/journal.pone.0007315.g006
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regulated, e.g. Icam2 (intercellular adhesion molecule 2) (29.4-
fold), Pecam1 (platelet/endothelial cell adhesion molecule 1)
(25.4-fold), Sell (selectin, lymphocyte) (28.6-fold), Cdh5 (cadherin
5) (28.4-fold), Itga1 (integrin alpha 1) (24.0-fold) and Itga8
(integrin alpha 8) (216.1-fold) in adenocarcinoma vs transgenic
cells. Specifically, Chl1 is a member of the immunoglobulin
superfamily of neural cell adhesion molecules and it is highly
expressed in the central and peripheral nervous systems [42,43],
but, L1 homologues have been described for other cell types of
diverse origin as well, including endothelial cells, epithelial cells,
reticular fibroblasts, and cells of lymphoid and myelomonocytic
origin [44,45,46]. Several studies link L1 to motile processes
involved in tumor cell extravasation and glioma dissemination in
the brain [47]. Recent reports link L1 expression to melanoma
metastasis [48] and ovarian and uterine carcinomas associated
with poor clinical outcome [49] but, regulation of Chl1 in lung
cancers is novel and may act as coreceptor for integrin and growth
factors [50]. In this regard, Icam2, i.e. a member of the
immunoglobulin supergene family of adhesion proteins that serves
as the counter-receptor for leukocyte function-associated antigen-1
(LFA-1/or CD11a/CD18) is of considerable interest [51]. It is
closely related to Icam1, but has only two Ig-like extracellular
domains, as compared with the five Ig domains of Icam1 [52].
Icam2 cytoplasmic tail can interact with ezrin in vitro. Ezrin is a
member of the ERM (ezrin, radixin, and moesin) family, which
can function as a linker between the plasma membrane and the
actin cytoskeleton [53]. Recently, it has been reported, that an
increased Icam2 expression on cancer cells enhances the adhesion
and reinforces the cytotoxic activity of immune cells such as NK
cells, resulting in a reduction of metastasis [54]. We found Sell (L-
selectin) to be regulated which codes for a lectin-binding protein
and known to be expressed by leukocytes. This adhesion molecule
mediates the initial attachment of leukocytes to endothelial cells,
which allows leukocytes to roll along the venular wall [55,56].
Lymphocytes and neutrophils exhibit a reversible loss of Sell
expression after cellular activation that results from endoproteo-
lytic release of the receptor from the cell surface [57]. Soluble Sell
is functionally active and is present at high levels in human plasma.
Decreased levels of L-selectin are observed in the serum of patients
who develop adult respiratory distress syndrome [58]. It has been
shown that Sell is able to transmit intracellular signals, including
increased tyrosine phosphorylation and activation of MAP kinase
in neutrophils [59]. There is increasing evidence for Pecam1 a cell
adhesion molecule to interact with integrinavb3 and plays a role in
angiogenesis [60]. Moreover, endothelial cell tube formation
depends on Pecam1 and cadherin 5 [61], which, in our study,
were down-regulated. In this regard cadherin 5, a major cadherin
Figure 7. Ingenuity networks: adenocarcinoma versus non-transgenic mice. Ingenuity networks generated by mapping the focus genes
that were differentially expressed between tumor and non-transgenic unaltered lung tissue (part I).
doi:10.1371/journal.pone.0007315.g007
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cell junctions [62]. Cadherins are organized in junctional
structures, i.e. adherens junctions. In such junctions, cadherins
are clustered and connected through their cytoplasmic domain
with a complex network of cytoskeletal proteins. Through their
homophilic interactions, they play a role in sorting cells of different
lineages during embryogenesis, establishing cell polarity, as to
maintain tissue morphology and cell differentiation [63,64].
Regulation of tight and gap junctions
We found Cldn5 (claudin 5) to be significantly repressed in lung
adenocarcinoma. A functional relationship has been proposed for
Cdh5 to control Cldn5 expression [65]. Specifically, Claudin 5 is a
major claudin identified in normal endothelial cells [66] but is also
expressed in type II alveolar epithelial cells [67]. It forms
homooligomeres and is localized at the apical-tight junction
region in both bronchi and bronchioles [68].
Furthermore, many reports suggest that adherens junctions (AJs)
and tight junctions to be interconnected and that AJs influence
tight junction organization. Regulation of claudin 5 expression by
cadherin 5 may therefore reinforces such crosstalk between tight
and adherens junctions to promote tumor growth and metastasis.
We found Cldn2 (13.4-fold) significantly up-regulated in
adenocarcinoma. Cldn2 (claudin 2) has been shown to modify
tumor invasion by the regulation of matrix metalloproteinases
(MMPs). Both claudin 2 and claudin 5 are able to activate
membrane-type 1-MMP-mediated pro-MMP-2 processing. Re-
portssuggest members oftheclaudin-family to be modulatedduring
oncogenic transformation and may therefore play an important role
in influencing tumor progression and invasion [69,70].
Besides significant regulation of tight junction coding genes we
found the gap junction protein Gja5 (gap junction membrane
channel protein alpha 5 or so called connexin 40) 27.3-fold down
regulated in adenocarcinoma and 28.7-fold repressed when
compared to non-transgenic cells. Gja5 is a member of the
connexins and encodes a gap junction protein that is highly
expressed in lung, vascular endothelium, and portions of the
cardiac conduction system [71]. Recent studies confirmed Gja5/
Cx40 gene expression in lung tissue [72] and that Gja5/Cx40 was
expressed similarly in normal lung and small size lung tumors, but
its expression decreased in large size tumors [73]. Notably,
aberrant gap junctional intercellular communication is an
important feature of malignant cells and allows neoplastic cells
to escape the tissue-specific growth control [74,75].
Regulation of tyrosine kinase receptors and their ligands
Several studies have examined the role of growth factor
receptors and their ligands in the activation of Ras. Therefore
Figure 8. Ingenuity networks: adenocarcinoma versus non-transgenic mice. Ingenuity networks generated by mapping the focus genes
that were differentially expressed between tumor and non-transgenic unaltered lung tissue (descriptions see Fig. 6) (part II).
doi:10.1371/journal.pone.0007315.g008
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observed 5 genes to be up-regulated ranging between 6.3-26.6-
fold, e.g. Areg (amphiregulin), Ereg (epiregulin), and up to 70
genes down-regulated (23.8 to 229.4-fold), e.g. Fgf7 (fibroblast
growth factor 7), Fgfr4 (fibroblast growth factor receptor 4), Pdgfb
(platelet-derived growth factor beta polypeptide)), Vegfd/Figf (c-
fos induced growth factor) and Vegfr2/Kdr (vascular endothelial
growth factor receptor- 2) when transgenic but morphologically
unaltered lung tissue was compared with adenocarcinomas.
Likewise, 12 genes were up-regulated between 7.4 to 598.1-fold
and 71 genes were down-regulated (24.1 to 230.4-fold) when
compared to non-transgenic lung tissue. In particular, the Areg
(amphiregulin) and Ereg (epiregulin), ligands of the epidermal
growth factor receptor (Egfr) were highly significantly upregulated
(up to 600-fold). It has been suggested that elevated expression of
Areg and Ereg may play an important role in tumor growth and
result in chronic Egfr stimulation followed by increased prolifer-
ation. Indeed, epiregulin is normaly repressed in human cells but
reported to be extensively activated in tumors [76] but one study
showed that activation of telomerase and subsequent induction of
epiregulin are required for sustained cell proliferation [77].
Likewise, Areg transcript was identified in a variety of human
tumors [78]. Importantly, recent evidence suggests Areg to inhibit
apoptosis in non-small cell lung cancer cell lines [79]. Besides the
significantly up-regulation of Areg and Ereg, we found fibroblast
growth factor 7 25.4-fold-down-regulated in adenocarcinoma and
26.4-fold down-regulated in adenocarcinoma vs non-transgenic
cells. Additionally, Fgfr4 was 215.2-fold and 218.6-fold down-
regulated in cancer. This monomeric receptor tyrosine kinase can
induce angiogenic, mitogenic and differentiation responses in cells
[80]. Dysregulation of this pathway was demonstrated in several
tumors including lung cancer [81] but unlike our study,
components of the FGF signalling pathway were reported to be
up-regulated [82].
In this regard, we found Vegfd/Figf (c-fos induced growth
factor) to be 228.7-fold down-regulated in adenocarcinoma as
compared to transgenic and 230.3-fold down-regulated vs non-
transgenic cells, while Vegfr2/Kdr (vascular endothelial growth
factor receptor- 2) was 27.1-fold and 28.3-fold repressed,
respectively. Specifically, Vegfd is a ligand for the Vegf receptor
tyrosine kinases and activates the structurally similar type III
receptor tyrosine kinase Vegfr3 [83]. Recently, it was shown that
Vegfr2 mRNA level in peripheral blood was increased in NSCLC
patients when compared with healthy individuals [84]. However,
this finding is not supported by our results. Note, in the context of
angiogenesis we found angiopoietin 1 (Angpt1) and tyrosine kinase
with immunoglobulin and epidermal growth factor homology
domains (TIE1) also down regulated in adenocarcinoma. Both
molecules are involved in vascular homeostasis, vascular integrity
and angiogenesis.
A further down regulated gene was PdgfB (platelet-derived
growth factor beta polypeptide). It was 24.0-fold repressed in
adenocarcinoma compared with transgenic but otherwise unaltered
cells and 24.6-fold down regulated in adenocarcinoma compared
with non-transgenic. Importantly, the B chain of Pdgf is the cellular
homologue of the v-sis oncogene, which is known to cause simian
sarcoma [85,86] and a homodimer composed of two B chains is a
potent mitogen for a variety of cells [87]. Although the contribution
of PdgfB in tumour genesis is not fully clarified, the co-expression of
PdgfB and its receptors has been described in many tumours, and
autocrine PdgfB stimulation in these tumours has been suggested
[88,89]. It was shown that exon 1 of PdgfBwasdeleted and replaced
by a variable segment of collagene 1A1 gene [90] thereby activating
the v-sis oncogene in experimental models [91].
Pertubation in Lipid metabolism
Numerous investigations have demonstrated changes in lipid
metabolism in cancer patients, as well as aberrant lipid utilization
by tumor cells [92,93]. Therefore we examined genes involved in
lipid metabolism and found 11 genes in adenocarcinoma to be
regulated ranging from 23.6 to 223.1-fold. In particular Hpgd
(15- hydroxyprostaglandin dehydrogenase) was significantly
223.1-fold down regulated in adenocarcinoma vs transgenic and
226.6-fold down regulated in adenocarcinoma vs non-transgenic
cells. Note, this dehydrogenase is highly expressed in the lung and
a key catabolic enzyme to control the biological activity of
prostaglandins [94,95,96], by converting PGE2 into the less active
metabolite 15-hydroxy-PGE2. In addition to the prostaglandins,
the 2 v - 6 hydroxy fatty acids, 15HETE; 5,15-di-HETE; 8,15-
diHETE [97] and lipoxin A, [98] are also substrates for Hpgd. A
small but significant increase in PGE2 in the lungs of Hpgd knock
out animals was reported [99].
Next, we found Pitpnc1 (phosphatidylinositol transfer protein,
cytoplasmic, 1) 212.0-fold down regulated in adenocarcinoma vs
transgenic and 214.2-fold down regulated compared with non-
transgenic. The Pitpnc1 belongs to a family of phosphatidylinositol
transfer proteins and recent studies suggest Pitp to be required to
maintain levels of PI(4,5)P2 during G-protein coupled Plcb
signalling [100].
The Pltp (phospholipid transfer protein) was also 27.5-fold
down regulated in adenocarcinoma vs transgenic and 28.6-fold as
compared to non-transgenic cells. This transfer protein is a
member of the lipid transfer/lipopolysaccharide binding protein
gene family, that play a major role in the metabolism of HDL,
vitamin E and lipopolysaccharide [101]. Pltp facilitates cholesterol
efflux from cells and, enhances the transfer of surface remnants
from triglyceride-rich lipoproteins to HDL during lipolysis
[102,103].
Regulation of acyltransferases
Next to lipid metabolism we examined genes involved in
carbohydrate metabolism and found several acetyltransferases to
be regulated.
For example, Oact1 (O-acetyltransferase (membrane bound)
domain containing 1) was 6.4-fold up-regulated in adenocarcino-
ma when compared with transgenic but healthy cells. Oact1
belongs to the family of membrane-bound O-acyltransferases
(MBOATs) which are important for membrane phospholipids
biosynthesis [104]. Oact1 contributes to the turnover of phospho-
lipids and is involved in catalysis of membrane biogenesis [105].
We observed altered expression of genes coding for cell surface
glycolipids in adenocarcinoma. Several were already up-regulated
in dysplasia, for example St8sia6 (St8 alpha-n-acetyl-neuraminide
alpha-2,8-sialyltransferase 6), Orm1 (orosomucoid 1) and Gpc6
(glypican 6). In adenocarcinomas, the expressions of these
molecules were also increased. In contrast, we found chondroitin
sulfate proteoglycan 4, UDP-N-acetyl-alpha-D-galactosamine:
polypeptide N-acetylgalactosaminyltransferase-like 4, 1-acylgly-
cerol-3-phosphate O-acyltransferase 4, ST8 alpha-N-acetyl-neur-
aminide alpha-2,8-sialyltransferase 2, glycoprotein Ib/beta poly-
peptide, lecithin-retinol acyltransferase, glycoprotein m6a,
carbohydrate sulfotransferase 1 were up to -20-fold down
regulated.
Specifically, chondroitin sulfate proteoglycan 4, a cell surface
proteoglycan is known to regulated in the adhesion, migration and
invasion of tumor cells such as human melanoma and infantile
acute myeloid leukemia [106]. The second down regulated
glycoprotein was glycoprotein Ib/beta polypeptide, a platelet
surface membrane glycoprotein that functions as a receptor for
Lung Cancer Genomics
PLoS ONE | www.plosone.org 9 October 2009 | Volume 4 | Issue 10 | e7315von Willebrand factor [107] and was shown to affect receptor
endocytosis and recycling [108]. We found glycoprotein m6a
219.5-fold down regulated in adenocarcinomas. Additionally, 1-
acylglycerol-3-phosphate O-acyltransferase 4 also known as
lysophosphatidic acid acyltransferase was 25.0-fold down regu-
lated in adenocarcinomas. This enzyme is a crucial for synthesis of
glycerolipids as well as triacylglylcerol biosynthesis. It catalyses the
acylation of lysophosphatidic acid (LPA) to form phosphatidic acid
(PA), the precursor of all glycerolipids [109].
We also observed the ST8 alpha-N-acetyl-neuraminide alpha-
2,8-sialyltransferase 2 to be nearly 6-fold down regulated in
adenocarcinoma. This transferase catalyzes the polycondensation
of alpha-2,8-linked sialic acids to polysialic acid (PSA) and the
attachment of polysialic acid to the carrier molecule e.g. Ncam.
Polysialic acids are implicated in numerous normal and pathologic
processes, including tumor metastasis [110]. A further down
regulated transferase was lecithin-retinol acyltransferase (phospha-
tidylcholine-retinol-O-acyltransferase). We found Lrat up to -13-
fold down regulated in adenocarcinoma. This enzyme is essential
in the processing of vitamin A and is responsible for conversion of
all-trans-retinol into retinyl esters [111].
Regulation of embryonic development programs
Cancer cells utilise embryonic programms for instance by
producing blocking factors to inhibit the immune system from
attacking them. Here, we focused on genes coding for molecules
involved in cellular development and found 9 genes up-regulated
ranging between 5.9 to 26.6-fold and 56 genes down-regulated
ranging from 23.6-fold to 229.4-fold in adenocarcinoma.
This included Fst (follistatin) which we found 6.3-fold up-
regulated. This single chain autocrine glycoprotein [112] is a
functional antagonist of several TGF-b proteins such as activin A
[113,114]. Follistatin is involved in the development of the embryo
and has inhibitory action on bone morphogenic proteins (BMPs)
[115,116]. Notably, Bmp6 (bone morphogenetic protein 6) was
significantly 229.4-fold down regulated in adenocarcinoma when
compared with transgenic cells and 235.2-fold down regulated in
adenocarcinoma versus non-transgenic cells. Bmps are part of the
transforming growth factor (TGF)-b super-family of secreted
signaling molecules [117]. Growing evidence suggest deregulation
of follistatin and activin to contribute to cancer development and
metastasis [118,119,120].
Furthermore some of the homeobox genes, e.g. Hoxa5, Hoxb5,
Meis1 and Mrg1 were up to 9-fold repressed in adenocarcinomas.
During morphogenesis Hox factors specify body segments [121] and
are expressed in defined and often overlapping domains along the
anterior-posterior axis. It has been shown that Hox proteins work
together with many other transcription factors in a combinatorial
fashion [122]. Importantly, Hoxa5 and Hoxb5 play a role in
morphogenesis and early differentiation of lung [123,124] and the
extent of transcript expression correlates with the level of
methylation [125]. Promoter methylation could be involved in
tissue specific silencing of these genes and had been reported for the
Hoxa5 gene in lung cancer [126], in human breast tumors [127], in
myeloid and lymphoid malignancy [128] and for the Hoxb5 gene in
ovarian carcinomas [129] where the gene undergoes de novo
methylation. Additionally, it was shown that Hoxa5 up-regulates the
tumor suppressor gene p53 [127]. We observed regulation of Meis 1
and Mrg1 in adenocarcinomas. These encode homeobox proteins
belonging to the TALE (‘three amino acid loop extension’) family of
homeodomain-containing proteins and were first identified, as a
common viral integration site in myeloid leukemic cells of BXH-2
mice [130]. Meis1, Mrg1 and other members of the TALE family
serve as Hox cofactors by altering HOX-DNA binding specificity, to
increase DNA binding affinity thereby augmenting their transcrip-
tional activity [131]. Their coordinate regulation in adenocarcino-
mas as reported herein has also been shown in ovarian cancers [132]
and in the IMR32 neuroblastoma cell line [133].
Next to the homeobox genes we found members of the
transcription factors belonging to the SRY-related HMG (High
Mobility Group) box superfamily down regulated in adenocarci-
noma e.g. Sox7, Sox11 and Sox13 were repressed by 24.9 to
280.6 and 24.3-fold in adenocarcinoma compared with trans-
genic and 25.6 to 2101.0-fold in adenocarcinoma versus non-
transgenic. They are involved in a number of developmental
processes and are expressed in a cell-specific way [134].
Deregulations of Sox genes are associated with a large number
of tumour types in vivo [135,136,137].
Specifically, Sox7 plays a critical role in endoderm differenti-
ation. The silencing of Sox7 was shown to be inhibited by Gata-4
and Gata-6, which are transcription factors as well [138]. Sox7
mRNA is highly expressed in adult lung but down-regulated in
lung cancer [139]. In prostate cancer tumor-specific promoter
hypermethylation of Sox7 was reported [140]. Additionally, we
observed regulation of Sox11
Next, we observed repression of Gata nuclear transcription
factors. GATA-6, a member of the GATA family of zinc finger
proteins, is the only family member known to be expressed in the
epithelial cells of the developing airway epithelium [141]. It has
been reported that a deficiency of Fog2 (Friend of Gata 2), causes
loss of the accessory lobe and anterior right medial lobe of the
mouse lung with relatively good preservation of other structures
[142] and that a Fog2-Gata4 interaction is critical for the
development of normal pulmonary lobar structure [143]. Here
we evidence Gata-2 and Gata-3 to be up to 212.7-fold down
regulated in adenocarcinoma. These factors have been shown to
play essential roles in development, such as for hematopoietic
progenitor cell function [144].
Regulation of tumor suppressors
Expression of the tumor suppressors mutated in colorectal
cancers (Mcc), hairy/enhancer-of-split related with YRPW motif 1
(Hey1), FAT tumor suppressor homolog 3 (Fat3), armadillo repeat
containing, X-linked 1 (Armcx1) and reversion-inducing-cysteine-
rich protein with kazal motifs (Reck) was significantly up to 214.0-
fold repressed in adenocarcinomas.
Notably, the Mcc tumor suppressor gene was found to be
mutated in several colorectal tumors [145]. This membrane-
associated cytoplasmic phosphoprotein blocks cell cycle progression
from the G0/G1 to the S-phase [146] and therefore plays a role in
cell cycle progression. Decreased Mcc mRNA levels were shown in
neoplastic mouse lung tissueand cell lines [147].Importantly,loss of
heterozygosityat the Apc/Mcc gene cluster on chromosome 5q21 is
frequent in non-small lung cancer [148]. We also observed
repression of Fat3, a planar cell polarity signalling molecule in the
Drosophila wing and a member of the cadherin superfamily [149].
Additionally, Hey1 was up to 210.0-fold repressed in
adenocarcinoma. This basic helix–loop–helix transcription family
plays a role in blood vessel formation and is involved in
proliferation, migration, and network formation of endothelial
cells [150]. It is induced during endothelial cell tube formation and
down-regulates vascular endothelial growth factor (VEGF) recep-
tor 2 in endothelial cells [151]. Recently, it was shown that Hey1
activates p53 through repression of Mdm2 transcription [152].
Quantitative real-time PCR
Expression of 7 genes in adenocarcinoma, transgenic and non-
transgenic samples was examined by quantitative real-time PCR
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egulin (Areg), epiregulin (Ereg), fetuin beta (Fetub), claudin 2
(Cldn2), hepatic nuclear factor 4, alpha (Hnf4a), glutathione S-
transferase, alpha 4 (Gsta4) and forkhead box A3 (Foxa3) were up-
regulated in adenocarcinoma (Supplementary Figure S3 and S4).
The expression data generated by the oligonucleotid array and
RT-PCR agreed well, therefore supporting the reliability of the
array analysis (Figure 9).
Immunohistochemistry
To further validate gene expression data we performed
immunohistochemical staining for some of the differentially
expressed genes (Figure 10, 11, 12). Immunohistochemistry using
antibodies targeted against Cldn2 (claudin 2), Fetub (fetuin beta),
Fst (follistatin), Orm1 (orosomucoid 1), S100a14 (S100 calcium
binding protein A14), Mcc (mutated in colorectal cancers),
RasGRF1 (guanine nucleotide-releasing factor 1), Reck (rever-
sion-inducing-cysteine-rich protein with kazal) and Cdh5 (cadher-
ine 5) confirmed the array data (Figure 10, 11 and 12). Notably,
Cldn2, Fetub, Fst, Orm1, S100a14 and RasGRF1 were primarily
detected in the cytoplasm of bronchial normal cells and tumor
cells. Overall, tumor cells showed higher levels of protein
expression than histologically normal bronchial epithelium. In
the case of Fst and RasGRF1 strong cytoplasmic and nuclear
staining was observed, where as the expression of Cldn2 was
restricted to the cytoplasm and patchy throughout neighboring
cancer cells. Importantly, in the case of Cdh5 and the tumor
suppressors Mcc and Reck tumor cells are largely unstained while
the underlying stroma and the control lung tissue was positive. In
Figure 13 expression of Hnf4a in dysplasia (10) and cancer (11) is
depicted. Consistent with Hnf4a mRNA levels the Hnf4a protein
levels were elevated in dysplasia as compared to adenocarcinomas.
Discussion
Cancer genomics provides valuable insight into molecular
abnormalities associated with the different stages of disease, i.e.
from low and high grade dysplasia to malignant transformation.
Here we report a comprehensive lung cancer genomic study in a
transgenic mouse model that recapitulates distinct genetic events
associated with adenocarcinomas. Distinguishing between differ-
ent stages of disease provides important information for transla-
tional research both from a diagnostic point of view and with
regards to novel therapeutic interventions.
Notably, lung cancer is a multistage process to result in
perturbations of normal cellular regulatory mechanisms that
ultimately leads to unchecked proliferation, infiltrative growth
and metastasis. By use of whole genome arrays we were able to
probe comprehensively for altered transcript expression associated
with either transgenicity or dysplasia or cancer. Through
advanced data analysis we could filter ‘‘genomic noise’’ and thus
searched for regulatory networks in lung adenocarcinomas. Based
on our recent study on dysplasia of respiratory epithelium [8] we
suggest a sequence of events, i.e. nuclear atypia with low and high
grade dysplasia followed by malignant transformation in fast
growing highly undifferentiated tumor. Through an application of
various bioinformatics tools networks could be constructed that
appear to be hallmarks at distinct phases of tumor development
therefore enabling fingerprinting of genes associated with
pathological phenotypes. Indeed, the microarray study provided
a wealth of information that allowed for hypothesis generation to
earmark the switch from dysplasia to malignant transformation
and the discovery of molecular events in lung cancer induced by
exaggerated c-Raf activity (Figure 14).
As denoted by many investigators perturbation of signaling
pathways may result in disruption of cell cycle regulation and of
Figure 9. Comparison quantitative RT-PCR and Oligonucleotid-Array. Summary of differential expression of the seven genes verified by
quantitative RT-PCR in comparison with Oligonucleotid-Array analysis. The data were analyzed statistically using Student’s t-test (*p,0.05; **p,0.01).
Error bars indicate standard deviation of five samples and two independent assays for each gene.
doi:10.1371/journal.pone.0007315.g009
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with adenocarcinomas in a transgenic mouse model that already
allowed us to asses precancerous stages of lung cancer induced by
c-Raf. Particularly, the RAS proto-oncogen family (K-ras, H-ras,
N-ras) codes for plasma membrane proteins. A mutation in the
RAS gene inadequately extendes Ras-Raf-MAPK signaling to
forster cell division. Approximately 90% of all ras mutations affect
the K-ras gene, of which 85% occur in codon 12. K-ras mutations
occur in particularly high frequency in adenocarcinoma (20–30%)
but sequencing of k-ras and c-raf of our transgenic tumor model
did not evidence any sequence alteration (data not shown). We
therefore describe a tumor model where amplification of a
aberrantly active c-Raf protein induced lung cancer. Indeed,
undue activity of c-Raf in human lung cancer has been reported
[10,11].
We combined the power of microdissection with genome wide
expression profiling. Because of the considerable heterogeneity of
cells in and around tumor sites microdissection allowed us to
harvest pure cell populations. Consequently, contamination of the
investigated tumor cells by normal epithelial cells, blood vessels
and cancer necroses that would otherwise result in misleading
information can be avoided [153]. Based on our recent report on
dysplasia and the findings of the present study we put forward a
model for successive stages of disease, with dysplasia being at the
edge of malignant transformation. We identified processes
specifically regulated in dysplasia that is a facultative cancer. This
included altered cell-to-cell signaling and cell-to-cell interaction,
perturbations in lipid metabolism, glycosylation, an array of post
translational modifications as well as undue regulation of
development and cellular movement programs [8].
We then compared regulation of genes in dysplasia with tumors
and identified up-regulated genes in adenocarcinoma, some of
which were already over expressed in dysplasia. These genes
coded particularly for components of receptor tyrosine kinases and
biological onthologies assigned to cell-to-cell signalling, lipid
metabolism, development and cancer. In dysplasia, however and
unlike adenocarcinomas, we could not evidence perturbations in
other signalling pathways such as MAPK, JAK/STAT, Wnt,
PI3K/AKT and Notch. Notably, many genes were repressed in
adenocarcinomas and could be grouped into the GO terms cell-to-
cell signaling, cell adhesion and metabolism, regulation of
development as well as repression of tumor suppressor genes.
Indeed, many growth factor receptors mediate their cellular effects
by intrinsic tyrosine kinase activity, which in turn, may
phosphorylate other effector molecules involved in mitogenesis.
A number of transforming oncogene products have growth factor
or growth factor receptor-like activities that work via a tyrosine
kinase-activating mechanism. We found members of vascular
endothelial growth factor receptor family deregulated, such as
Vegfr and Vegfd. Vegf is a key mediator of tumor angiogenesis
[154] and inhibition of Vegf is a targeted approach in cancer
therapy. Specifically, bevacizumab, a recombinant anti-vascular
Figure 10. Immunohistochemical staining for adenocarcinoma (Cldn2, Fetub, Fst). (a) Immunohistochemical staining of control lung
tissue, (b) lung cancer at 106magnification and (c) at 406magnification (d) lung cancer in the presence of primary antibody, after preincubation
with blocking peptide and (e) positive control. 1=claudin 2 (Cldn2), 2=fetuin beta (Fetub), 3=follistatin (Fst).
doi:10.1371/journal.pone.0007315.g010
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the therapy of NSCLC. It was shown that addition of
bevacizumab to chemotherapy (carboplatin/pacilitaxel) signifi-
cantly improved overall survival, as well as progression-free
survival and response rates [155]. However, our findings imply
that in advanced tumor stages of adenocarcinoma members of the
Vegf family are down regulated. This agrees well with the clinical
observation of poor success of antiangiogenic therapies in
advanced stages of disease [156]. In our tumor model aberrant
expression of other members of the mitogen-activated protein
kinase (MAPK) pathway was observed as well. As the MAPK
pathway mediates a variety of responses to extracellular stimuli,
dysregulation of some of its components in tumor cells was of no
surprise to us and has been denoted by other investigators [157].
Furthermore, the observation that post-translational modifications,
such as farnesylation are required for membrane localization and
activation of Ras, has led to an interest in developing Ras
inhibitors for varoius tumors, including leukemias, non small cell
lung cancer, prostate, breast, pancreatic, and colorectal cancers by
inhibiting farnesyltransferases (FTIs). Although inhibition of K-ras
activity through inhibitors of farnesyltransferase could represent an
important strategy to block cell proliferation, clinical results
obtained to date have been disappointing [158]. Thus, the focus of
development of a more viable approach to inhibit the MAPK
pathway has turned to Raf and MEK. Sorafenib (BAY43-9006) is
an oral, dual inhibitor of Raf and vascular endothelial growth
factor receptor (VEGFR) and was initially developed as a specific
inhibitor of the serine/threonine RAF kinase, in particular c-Raf
(also known as Raf-1) and b-Raf [159]. The molecule has
demonstrated preclinical antineoplastic activity against a wide
spectrum of human cancers [160–164] eventhough some investi-
gator suggests highly selective Raf-inhibitors to display more
efficacy [165]. Indeed, XL-281 and PLX-4032 are oral inhibitors
with high selectivity against Raf and are in phase 1 clinical trials.
A further important finding of our study was the discovery of
regulated genes coding for cell adhesion. Notably, these molecules
are already discussed in association with metastasis as shown for
cadherin. Studies on the pathophysiology of metastasis of tumor
cells suggest that dysregulation of adhesion molecules for the
detachment of tumor cells from their primary cells are necessary
but require a complex cascade of adhesive interactions between
tumor cells and tissues. In the present study a variety of cell
adhesion molecules had changed expression in advanced cancer
growth that are involved in tight- and gap junctions such as the
claudins and gap junction protein 5. Notably, claudin 2 was
selectively expressed in lung adenocarcinomas, whereas claudin 5
expression was strongly repressed in lung tumors. Tight junction
proteins are integral membrane proteins, which interact with the
proteins of the neighboring epithelial or endothelial cell. They are
essential for the maintenance of cell polarity. Already in some
Figure 11. Immunohistochemical staining for adenocarcinoma (Orm1, Mcc, RasGRF1). (a) Immunohistochemical staining of control lung
tissue, (b) lung cancer at 106magnification and (c) at 406magnification (d) lung cancer in the presence of primary antibody, after preincubation
with blocking peptide and (e) positive control. 4=orosomucoid 1 (Orm1), 5=mutated in colorectal cancers (Mcc), 6=guanine nucleotide-releasing
factor 1 (RasGRF1).
doi:10.1371/journal.pone.0007315.g011
Lung Cancer Genomics
PLoS ONE | www.plosone.org 13 October 2009 | Volume 4 | Issue 10 | e7315tumors, such as in breast cancer and gastric cancer repression of
tight junction proteins was observed [166]. Dysfunction of these
proteins leads to the disruption of the tight junction, a process that
may play a major role in the loss of cohesion and poor
differentiation of tumor cell [167]. Moreover, by the loss of tight
junctions the orderly structure of tissue will no longer be
maintained and tumor cells detach more easily from the tumor
and invade surrounding tissues [166]. Therefore, alteration in tight
junctional communications represents an important molecular
mechanism in lung tumor progression.
Furthermore, genes involved in glycosylation of phospholipids
were significantly altered. Indeed, cell surface proteoglycans are
important in modulating cell adhesion and motility. Changes in
glycosylation patterns during transformation of normal cells into
cancer cells have been reported as to enable cancer cells to
improve cell to cell interaction and adhesion to extracellular
matrices.
Another finding of our study was the remarkable regulation of
hox genes in adenocarcinoma, for example Hoxa5, Hoxb5, Meis1
and Meis2. It is known that the hox genes act in early development
and code for transcriptional regulators that can turn genes on or
off. Regulation of developmental programs in malignancy is the
subject of intense research. Aditionally, we observed repression of
several tumor suppressors. Loss of tumor suppressor gene function
is germain to cancers.
Gene regulatory networks
We were particularly interested in identifying regulatory
networks associated with the switch from dysplasia to malignant
transformation. Based on bioinformatics analysis 75 genes were
regulated exclusively in dysplasia (Supplementary Figure S5 and
Supplementary Text S1), where as 387 genes could be attributed
to adenocarcinoma of which 39 genes were regulated in common
(Figure 15).
Common networks in dysplasia and cancer
Network 1 (Figure 16) shows the common regulated genes in
dysplasia and adenocarcinoma. The central components in this
network are Egf, Mapk and Tgf-b eventhough they are themselves
not regulated many of their downstream targets are. Notably, Areg
(amphiregulin) and Ereg (epiregulin) are ligands of the EGF
receptor tyrosin kinases and are members of the ERBB family
including EGFR (ERBB1) to function as activators. The EGFR
pathway stimulates cell proliferation and motility and overexpres-
sion of EGFR–ligands was observed in many kinds of cancer
including lung, breast and prostate cancer. Furthermore,
RasGRF1 (RAS protein-specific guanine nucleotide-releasing
factor 1) is a direct target of EGF. RasGFR1 enhances the release
of GDP that is required for Ras activation. There is cross-talk
between the EGFR and MAPK signaltransduction pathways.
Figure 12. Immunohistochemical staining for adenocarcinoma (Reck, Cdh5, S100A14). (a) Immunohistochemical staining of control lung
tissue, (b) lung cancer at 106magnification and (c) at 406magnification (d) lung cancer in the presence of primary antibody, after preincubation
with blocking peptide and (e) positive control. 7=reversion-inducing-cysteine-rich protein with kazal motifs (Reck), 8=cadherine 5 (Cdh5) and
9=S100 calcium binding protein A14 (S100A14).
doi:10.1371/journal.pone.0007315.g012
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further central component and is highly up-regulated. Based on
the chick chorioallantoic membrane angiogenesis and mouse
tumor angiogenesis assays it was postulated that Pthlh is a Pka
dependent angiogenesis inhibitor in vivo [168]. In this context
Fetuin B (Fetub) was identified as a downstream target of Pthlh.
Notably, up-regulated Fetub was reported for several tumors
[169].
A further target molecule in this network is Itih2 (inter-alpha-
trypsin inhibitors heavy chain2). This protein acts as plasma serine
protease inhibitor and stabilized extracellularmatrix proteins.
Down regulation of ITIH proteins and Itih2 in particular has
been reported in different types of cancer including breast and
lung cancer [170].
Furthermore, Pcsk6 or PACE4 Paired Basic Amino Acid
Cleaving Enzyme is a proprotein convertase that mediates the
production of peptidic mitogens. Regulation of this gene was
reported for non-small cell lung cancers. Maybe it is involved in
autocrine production of mitogens contributing to unchecked
proliferation of tumor cells [171].
Additional members of this network are Ptprn2 (protein tyrosine
phosphatase, receptor type, N polypeptide 2) and Pkhd1
(polycystic kidney and hepatic disease 1), which act i.e. as signaling
molecule involved in cell growth, differentiation, mitotic cycle, and
oncogenic transformation. The Ptprn2 locus is reported to be
hypermethylated in lung cancer [172] while Pkhd1 (polycystic
kidney and hepatic disease 1) is associated with polycystic kidney
and hepatic disease. In recent works it was shown that Hnf1b is
required for the activation of the Pkhd1 promoter [173]. Finally,
Cdsn (Cornedesmosin) is downstream of Ubqln4 (ubiquilin 4) a
connexin43-interacting protein. Cds encodes for intracellular
structures participating in desquamation. It is normally expressed
in skin cells and until now regulation of this gene was not
associated with tumors.
Gene networks exclusively regulated in adenocarcinoma
Network 2 (Figure 17) consisted of predominantly down
regulated genes with the central components Vegf, Erk/Mapk and
Pdgf. Notably, Vegf plays pivotal roles in the regulation of
angiogenesis and function as a vascular permeability factor to
increase microvascular permeability. Importantly, in situ hybrid-
ization studies have demonstrated Vegf mRNA to be up-regulated
in the majority of human tumors. Only sections of lobular
carcinoma of the breast and papillary carcinoma of the bladder
failed to show significant Vegf mRNA expression [174]. The
biological effects of Vegf are largely mediated by the VEGF
receptor tyrosine kinase Kdr (kinase domain region) and c-fos
induced growth factor (Figf/Vegfd) all being direct targets of Vegf.
Indeed, Vegfd was localized in tumor cells and endothelium in
human non-small cell lung carcinoma [175]. The network displays
regulation of these molecules as well as Angpt1 (angiopoietin1),
which binds and activates the Tek/Tie2 endothelial-specific
receptor tyrosine kinase, Efnb2 (ephrinB2) [176], Cdh5 (cadherin
5) and Ptprb (protein tyrosine phosphatase, receptor type, B or
vascular endothelial tyrosine phosphatase). In recent works it was
reported that activation of Vegf/Vegfr2 and Angiopoietin/Tie2
signalling is modulated by BMP (bone morphogenetic protein)
signaling-activation in endothelium [177]. Notably, Bmp6 was
strongly down regulated in our transgenic adenocarcinoma model.
Further to pertubations in signalling pathways associated with
angiogenesis the network depicts various transcription factors
involved in angiogenesis as well.
Specifically, Hey1 (hairy/enhancer-of-split related with YRPW
motif 1) inhibits Vegfr2 [151] and indirectly activates p53 through
regulation of Mdm2 [152]. Recent work showed that Hey1,
through its interplay with Runx2, play an important role in
regulating Bmp9 [178]. Moreover, Hey 1 is a primary target of
Notch [179] with Notch 4 (Notch gene homolog 4) being down-
Figure 13. Hnf4a expression in dysplasia and adenocarcinoma. Hnf4a staining. 10=dysplasia, 11=adenocarcinoma (a) Immunohistochem-
ical staining of control lung tissue, (b) lung cancer at 106magnification and (c) at 406magnification (d) lung cancer in the presence of primary Hnf4a
antibody, after preincubation with blocking peptide and (e) positive control.
doi:10.1371/journal.pone.0007315.g013
Lung Cancer Genomics
PLoS ONE | www.plosone.org 15 October 2009 | Volume 4 | Issue 10 | e7315regulated in our transgenic mouse model. Specifically, Notch
proteins are single-pass transmembrane receptors that function as
nuclear transcriptional co-activators. Notch signalling is required
for vascular development and tumor angiogenesis. In fetal lung
development, Notch signalling appears to be essential for the lung
to achieve its normal size and Notch 1 and Notch 2 protein are
frequently expressed in human non-small cell lung cancer with
Notch3 mRNA expression being detected in 7 of 25 NSCLC cell
lines [180]. Furthermore, in murine keratinocytes Notch1
signalling stimulates expression of early differentiation markers
Figure 14. Schematic model of the lung tumor progression. Schematic model of the lung tumor progression based on molecular analyses of
various grades of lung cancer. Shown are changes in molecular processes whereby the number of regulated genes and not the direction of gene
expression were chosen.
doi:10.1371/journal.pone.0007315.g014
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up-regulated in adenocarcinoma and encodes a protein of the
terminally differentiated keratinocyte. It could be shown that in
the absence of mutant p53 involucrin was up-regulated in the
human lung adenocarcinoma cell line Anip973 [181].
A further component of the transcriptional network are the
GATA binding proteins 2 and 3, Lmo2 (LIM domain only 2) and
Klf2 (Kruppel-like factor 2). Note, Gata2 is expressed in the
precursor of hematopoietic cells and reduction of Gata2
expression or activity is required for differentiation into hemato-
poietic cells [182]. Gata3 expression is restricted to T-lymphoid
cells and some nonhematopoietic cell types, including embryonic
stem cells [183] but Lmo2 is necessary for early stages of
hematopoiesis, while the Lmo2 protein plays a central role in
angiogenesis [184]. The network implies Klf2 to be targeted by
PdgfB (platelet derived growth factor, B polypeptide). Recent
studies evidenced PdgfB to regulate Klf2 expression through Src
signalling which is also critical for vascular formation [185].
Several metabolic processes are connected in this network, e.g.
carbohydrate and lipid metabolism with Pcsk5 catalycing reactions
ranging from precursors for growth factors, such as Figf, to cell
surface receptors and viral surface glycoproteins [186]. An indirect
downstream regulated molecule of Pcsk5 is Lipg (lipase, endothe-
lial) and Plod2 (procollagen lysine, 2-oxoglutarate 5-dioxygenase 2)
that catalyzes hydroxylation of lysyl residues in collagens.
Recently, Chang et al proposed Plod2 as one of the fibroblast
core serum response genes associated with cancer progression
[187].
Next to angiogenic signalling key components of the Erk/
Mapk1 (mitogen-activated protein kinase 1) are depiceted.
Although Erk is not regulated by itself it is a target molecule of,
for instance, Figf (c-fos induced growth factor), Thbd (thrombo-
modulin), Cspg4 (chondroitin sulfate proteoglycan 4), C1QTNF2
(C1q and tumor necrosis factor related protein 2), Plcl1
(phospholipase C-like 1), RasGRP3 (RAS, guanyl releasing protein
3) and Ptgfr (prostaglandin F receptor). A direct target molecule
displayed in this network are Reck (reversion-inducing-cysteine-
rich protein with kazal motifs) and ATP1A2 (ATPase, Na+/K+
transporting, alpha 2 polypeptide).
A further important member of this network is the prostaglan-
din F receptor, i.e. a member of the G-protein coupled receptor
family that plays central roles in the contraction of smooth muscles
of the bronchus and trachea [188]. It was reported that an
activation of EGFR-Ras-mitogen-activated protein kinase/Erk
kinase (MEK) via the Ptgfr resulted in an increase in Vegf
promoter activity, expression of Vegf mRNA, and secretion of
VEGF protein [189].
Network 3 describes interaction partners in the control and
the dynamic of the cytoskeleton and the cell mobility in lung
tumors. Of all regulated genes in this network only one is up-
regulated (Figure 17).
Notably, the up-regulated Kng1 (kininogen 1) generates two
isoforms of high molecular weight kininogen (Hmwk) and low
molecular weight kininogen (lmwk). Hmwk is important for the
assembly of plasma kallikrein. Kallikrein is assumed to play a role
in angiogenesis of prostate and breast cancer [190].
Figure 15. Venn diagram for the intersection of significantly differential expressed genes in dysplasia and adenocarcinoma.
Comparison of tumor and transgenic unaltered lung tissue with non-transgenic samples (426 genes) and comparison of dysplasia versus transgenic
and non-transgenic (114 genes).
doi:10.1371/journal.pone.0007315.g015
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F-actin, the latter being a filamentous polymer of the cytoskeleton.
In non muscle cells it serves as trail for myosin transporters and is
necessary for the cell motility. Motility is important for invasion
and metastasis in cancer. F-actin has four partners and besides
myosin in this network, their are Ablim3, Actc1 Rasgrp2 and Eng
depicted. Indeed, Ablim3 (actin binding LIM protein family,
member 3) is an actin binding Zn-finger protein. While Lim
domain proteins are known to be regulated in embryonic
development and in cancer it is postulated that Ablim3 functions
as linkage between the actin cytoskeleton and signaling pathways
[191]. Furthermore, Actc1 (actin, alpha, cardiac muscle 1) belongs
to the actin sub family of alpha actins which can be found in
muscular tissue. Likewise, Rasgrp2 (RAS guanyl releasing protein
2) is a nucleotide (GDP/GTP) exchange factor that activates ras
subfamily GTPases. The localization of Rasgrp2 to the membrane
seems to be directly associated with the polymerization of F-actin
[192]. Furthermore, Eng (endoglin) encodes for a homodimeric
transmembrane protein that is part of the Tgf-b receptor complex
with high affinity to Tgf-b1 and Tgf-b3. It could be shown that
Eng is a possible prognostic marker of prostate cancer [193].
Specifically, myosin, a direct interacting partner with F-actin, is
a motor protein. Three regulated genes surround myosin in
t h en e t w o r k :M y h 1( m y o s i n ,h e a v yp o l y p e p t i d e1 0 ,n o n - m u s c l e ) ,
Tnnc1 (troponin C, cardiac/slow skeletal) and Gzma (granzyme
A).
In the same network several partners around NF-kappa-B are
displayed, i.e. Vsnl1 (visinin-like 1), G0s2 (G0/G1switch 2), S1pr3
(sphingosine-1-phosphate receptor 3), Ankrd1 (ankyrin repeat
domain 1), Igfbp2 (insulin-like growth factor binding protein 2)
and Amph (amphiphysin). Notably, Vsnl1 (visinin-like 1) belongs
to the visinin/recoverin subfamily of neuronal calcium sensor
proteins and is normally expressed in granule cells of the
cerebellum. It is responsible for intracellular modulation of
signaling pathways. The participation of Vsnl1 in the regulation
of proliferative and invasive properties within neuroblastoma has
already been suggested [194]. Also, G0s2 (G0/G1switch 2) is
suggested to be phosphorylated by protein kinase C and casein
kinase II. It is postulated to be a target gene in all-trans-retinoic
acid (RA) treatment of acute promyelocytic leukemia [195], where
as sphingosine-1-phosphate receptor 3 belongs to the EDG
(endothelial differentiation gene) receptor family of g protein
coupled receptors. The receptor appears to be the target for
sphingosine-1-phosphate in angiogenesis. A further member in this
network is ankyrin repeat domain 1 (cardiac muscle), a
transcription factor induced by IL-1 and upon TNF-alpha
stimulation. In ovarian cancer a connection between expressions
level of Ankrd1 and treatment with platinum based chemotherapy
Figure 16. Ingenuity networks: common regulated genes in dysplasia and adenocarcinoma. Ingenuity networks generated by mapping
the focus genes that were common expressed between dysplasia and adenocarcinoma.
doi:10.1371/journal.pone.0007315.g016
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binding protein 2. Indeed, overexpression of Igfbp2 in transgenic
mice led to decreased appearance of dysplastic aberrant crypt foci
and inhibited the growth of adenomas [197].
Furthermore, amphiphysin that encodes a protein involved in
clathrin-mediated endocytosis is displayed. It may function as
linker of clathrin coat proteins and membrane curvature sensor.
Regulation of endocytosis may impact Cdk5 dependent phosphor-
ilation of amphiphysin [198]. Amph is further connected to
tubulin and Vtn (vitronectin) which is connected to the previously
described Kng1 and Itga8 (integrin alpha 8). Noteworthy, leucine
rich repeat protein 3 facilitates the Egf induced MAPK
phosphorylation and may be engaged in internalization of EGF
by clathrin-coated vesicles while neurocalcin delta being a part of
the neuronal calcium sensor family of calcium-binding proteins. It
is postulated to have a regulatory effect on G-protein coupled
receptors.
Additionally, the down-regulated tubulin gene is positioned in
the center of three likewise regulated genes: Stmn2 (stathmin-like
2), Tubb4 (tubulin, beta 4) and Mapt (microtubule-associated
protein tau). Tubulin forms the microtubuli which is a part of the
cytoskeleton and mainly consists of two forms alpha and beta
tubulin. The microtubule is important for mitotic spindle
formation and therefore targeted in cancer therapy. Stathmin-
like 2 is a microtubule regulator that seems to destabilize the
microtubuli. Tubb4 (tubulin, beta 4) is an isoform of beta tubulin
and may be necessary for mitosis [199]. Finally, in this network
downstream partners of calmodulin are connected, e.g. Gucy1a3
(guanylate cyclase 1, soluble, alpha 3), Gucy1b3 (guanylate cyclase
1, soluble, beta 3) and Adcy8 (adenylate cyclase 8). Notably, while
Gucy catalyzes the conversion of GTP to cGMP and acts as
second messenger adenylate cyclase catalyses the formation of
cAMP out of ATP and is part of G-protein dependent signaling
pathways.
The fourth network in adenocarcinomas (Figure 17) depicts
several ligands of tyrosine kinases like Fgf7 (fibroblast growth
factor 7) and Pdgfbb (platelet derived growth factor, B polypeptide)
as regulated. Both growth factors are involved in angiogenesis.
Specifically, fibroblast growth factor-7, also known as keratinocyte
growth factor, is involved in the regulation of proliferation and
differentiation of alveolar epithelial type II (AEII) cells [200] and
bronchiolar epithelial cells [201]. Moreover, it was shown that
Fgf7 stimulate the synthesis of surfactant components in rat fetal
ATII cells, thereby promoting maturation of the lung epithelium
[202]. Additionally, overexpression or loss of expression of Fgf7
and of its specific receptor was reported for a variety of tumours
including lung cancer [203]. Further target molecules of PdgfB in
this network are EdnrB (endothelin receptor type B), Fom1 (flavin-
Figure 17. Ingenuity networks exclusively regulated in adenocarcinoma. Ingenuity networks generated by mapping the focus genes that
were exclusively regulated in adenocarcinoma.
doi:10.1371/journal.pone.0007315.g017
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protein 6) all of which were strongly down regulated. Ednrb is a G
protein-coupled receptor which activates a phosphatidylinoitol-
calcium second messenger system and mediates biological
responses from a variety of stimuli, including growth factors, such
as PdgfB, vasoactive polypeptides, neurotransmitters, hormones,
and phospholipids while EdnrB receptor activation leads to
bronchoconstriction. Importantly, downregulation of endothelin
receptor type B was observed in human tumor cells [204]. A
further molecule of this network is flavin-containing monooxy-
genase 1 that catalyzes oxidation of many molecules. It was shown
that in vascular smooth muscle cells from rat aorta PdgfB
increased the expression of rat Fmo1 mRNA [205]. Likewise,
bone morphogenetic protein 6 is a member of the TGF-b
superfamily and crucial for all stages of embryonic development,
including regulation of lung development and airway branching.
This molecule mediates antigrowth signalling by suppressing
proliferation. Recent evidence suggests epigenetic inactivation of
Bmp6 in NSCLC [206]. Increasing evidence is also suggestive for
crosstalk between BMP antigrowth signalling and Ras/MAPK
progrowth signalling. In the present study, we did not observe a
connection between BMP and MAPK at the transcriptional level
[207]. Nonetheless, there appears to be cross-talk between the
BMP and Wnt pathway. Thus, Wnt2 (wingless-related MMTV
integration site 2) is depicted as a downstream molecule of Bmp6.
So far such cross-talk has only been observed in cultured
endothelial cells where Bmp6 protein increases the expression of
Wnt2 mRNA [208]. Members of the Wnt pathway were reported
to be regulated in a number of cancers as well as embryogenesis.
Notably, Wnt2 is overexpressed in human colorectal carcinomas
but only up-regulated in a small subset of prostate cancer [209],
but is overexpressed in primary NSCLC and plays a role as
mediator of apoptosis in several cancers of epithelial origin [210].
A further downstream target of Bmp6 is Sdpr (serum deprivation
response). This protein is a substrate of protein kinase C and binds
phosphatidylserine (PS) in a calcium-independent manner.
Recently, it was shown that Sdpr expression is suppressed in
tumors of breast, kidney and prostate [211], but until now
regulation of this gene was not associated with lung cancers.
A direct target of PdgfB is phospholipase C (Plc). PLC isozymes
catalyze the hydrolysis of phosphatidylinositol 4,5-bisphosphate
[PtdIns(4,5)P2] to inositol 1,4,5-trisphosphate and diacylglycerol.
These two second messengers activate the serine/threonine-specific
protein kinase C (Pkc), which was repressed in adenocarcinomas
and functions as modulater for the release of calcium from
intracellular stocks. Altered expression of several Plc family
members was reported for human cancers. Specifically, Plc is
highly expressed in breast carcinomas, and in metastatic colorectal
tumor cell lines [212]. However, a greatly reduced mRNA
expression of the Plc-L gene was observed in a large portion of
lung carcinoma cells [213,214]. It was shown that PLC could be
activated by members of the Ras and Rho families of guanosine
trisphosphatases (GTPases) such as RapGEF3 (Rap guanine
nucleotide exchange factor3), which we observed to be regulated
as well. Downstream of Plc is the serine/threonine-specific protein
kinase C (Pkc). Deregulation of certain types of PKCs plays a role in
human lung carcinogenesis through loss of control of cell growth
and/or differentiation. Recently, atypical PKCzeta was shown to be
involved in the chemotaxis and cell adhesion of NSCLC cells with
integrin b1 facilitating this process [215]. Moreover, overexpression
of the Pkc gene in colon carcinoma cells causes growth inhibition
and decreased tumorigenicity [216]. CD97, a glycoprotein that is
present on the surface of most activated leukocytes and spans the
membraneseventimesisafurthermemberofthisnetwork.Todate,
three ligands have been identified for CD97. One ligand for CD97
is the a5b1 integrin. It was proposed that CD97 plays a role in
migration and adhesion of tumor cells [217].
Further regulated genes in network 4 are Icam2, Wisp2, Grap
and Kit. ICAM2 (intracellular adhesion molecule 2) a member of
the Ig superfamily of cell surface proteins that may act as an
activator of the PI3K/AKT pathway to promote cell migration
[218] eventhough expression levels of ICAM2 in peritoneal
metastases tend to be decreased as compared to primary lesions.
Thus, it was hypothesized that ICAM2 enhances the adhesion and
activation of immune cells such as natural killer cells, resulting in a
reduction of metastasis [219]. Additionally, WNT1 inducible
signaling pathway protein 2 was identified as growth factors. WISP
proteins bind to glycosaminoglycans and may function in
angiogenesis, stem cell differentiation, and cancers. It was shown
that WISP2 mRNA and protein levels were significantly reduced
as breast cancer progresses from a noninvasive to invasive type and
were almost undetectable in poorly differentiated cancers [220].
Likewise, GRB2-related adaptor protein (Grap), plays a central
role in signalling patways due to interaction with other signalling
molecules such as p36/38, Slp76 (lymphocyte cytosolic protein 2),
Shc (src homology 2 domain-containing transforming protein C1)
and Sos (son of sevenless homolog 1). Importantly, Grap appears
to be a negative regulator specific for the Erk pathway [221] but
little is known about its role in cancer. Additionally, we found the
kit oncogene in this network. Binding of stem cell factor (SCF) to
Kit receptor tyrosine kinase activates multiple signal transduction
components, leading to the activation of MAPK pathway [222],
phosphatidylinositol 3-kinase, and Jak/Stat signalling [223]. The
tyrosine kinase receptor c-kit and its ligand stem cell factor are co-
expressed in various solid tumors and were identified in 64% of
primary adenocarcinomas of the lung [224]. However, expression
of c-Kit progressively decreases during local tumor growth and
invasion of human melanomas [225]. In this regard one group
reported that c-kit expression was decreased in advanced stages of
ovarian cancer and was associated with decreased survival [226].
Further members of this network are Ddc (dopa decarboxylase),
Acvrl1 (activin A receptor, type II-like 1) and Lrat (lecithin-retinol
acyltransferase), but are not directly linked to other regulated
molecules in this network.
Taken collectively, we constructed several networks that were
associated either specifically with dysplasia (Supplementary Figure
S5) or adenocarcinomas. In dysplasia, we observed strongly up-
regulation of Hnf4a and some of its target molecules. Especially
target genes of Hnf4a are regulated which encoded proteins
involved in metabolic processes. Second, we found several
transcription factors overexpressed in dysplasia. In strong contrast,
down regulation of many genes involved in angiogenesis, early and
restructuring of the cytoskeleton was a prominent feature of
adenocarcinomas.
Taken collectively, our study enabled an identification of a
limited set of molecules particularly associated with either
dysplasia or advanced MAPK induced adenocarcinomas. The
differential gene expression profiles of dysplasia and adenocarci-
noma enebled an identification of specific molecules, to allow for
better molecular classification of dysplasia and an improved
understanding of the biology in the progression of disease.
Improvement in the survival rate of patients with adenocarcinoma
will depend upon better diagnosis. The aplication of cancer
genomics thus allowed for the construction of gene regulatory
networks for a better understanding of tumor biology and the
validation of a wealth of novel targets to be explored in innovative
treatment regimes of lung cancer. The role of non-coding RNA in
lung adenocarcinomas will be the subject of future studies [227].
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SP-C/c-raf model
SP-C/c-raf transgenic mice were obtained from the laboratory
of Prof. Ulf Rapp (University of Wu ¨rzburg, Germany), who bred
the mice in the C57BL/6/DBA/2 hybrid background. We kept
the SP-C/c-raf transgenic mice in the C57BL/6 background for at
least five generations.
Lung cancer samples were derived from 5 SP-C/c-raf mice
(aged 12–14 months); unaltered lung tissue were always isolated
from 5 transgenic mice (aged 5–7 months). Endogenous normal
lung tissue was studied of 5 non-transgenic mice (aged 7–10
months). The non-transgenic littermates (wild-type) served as
control for transgenic effects.
Mice were sacrificed and the lung tissues were immediately
frozen on dry ice and stored at 280uC until further analysis.
The histopathological diagnosis was based on routinely
processed hematoxylin-eosin stains.
Microdissection (LMPC – Laser Microbeam
Microdissection and Laser Pressure Catapulting)
From each frozen lung tissue 10-mm thick sections were
prepared and transferred on polyethylene napthalate foil-covered
slides (Zeiss, P.A.L.M. Microlaser Technologies GmbH, Bernried,
Germany).
The sections were fixed in methanol/acetic acid and stained in
hematoxylin. The desired cells were microdissected using the
PALM MicroLaser systems (Zeiss, P.A.L.M. Microlaser Technol-
ogies GmbH, Bernried, Germany) and collected in an adhesive
cap (Zeiss, P.A.L.M. Microlaser Technologies GmbH, Bernried,
Germany). Microdissected cells were resuspended in a guanidine
isothiocyanate-containing buffer (RLT buffer from RNeasy
MikroKit, Qiagen, Santa Clarita, CA, USA) with 10 ml/ml b-
mercaptoethanol to ensure isolation of intact RNA. Approximate-
ly an area of 6610
6 mm
2 were pooled from a specific layer of
interest in the same animal and used for RNA extraction.
Following microdissection, total RNA-extraction was performed
with the RNeasy Micro Kit (RNeasy MicroKit Qiagen, Santa
Clarita, CA, USA) according to the manufacturer’s instruction. A
standard quality control of the total RNA was performed using the
Agilent 2100 Bioanalyzer (Agilent Technologies, Palo Alto, USA).
cRNA labeling and hybridization to microarrays
Total RNA (median: 175 ng; range: 150–200 ng) was used to
generate biotin-labeled cRNA (10 mg) by means of Message Amp
aRNA Premium Amplification Kit (Ambion, Austin, TX). Quality
control of cRNA was performed using a bioanalyzer (Agilent 2001
Biosizing, Agilent Technologies). Following fragmentation, labeled
cRNA of each sample was hybridized to Affymetrix GeneChipH
Mouse Genome 430 2.0 Arrays covering over 34.000 genes and
stained according to the manufacturer’s instructions.
Quantification, normalization and statistical analysis
Array data was normalized using scaling or per-chip normal-
ization to adjust the total or average intensity of each array to be
approximately the same.
Microarray chips were analyzed by the GCOS (GeneChip
Operating Software) from Affymetrix with the default settings
except that the target signal was set to 500 and used to generate a
microarray quality control and data report.
CEL files exported from GCOS were uploaded into ArrayTrack
software (National Center for Toxicological Research, U.S. FDA,
Jefferson, AR, USA (NCTR/FDA)) and normalized using Total
Intensity Normalization after subtracting backgrounds for data
management and analysis. ArrayTrack software includes some
tools common to other bioinformatics software (e.g., ANOVA, T-
test and SAM).
SAM
To compare the normalized data from dysplasia, normal lung
tissue from transgenic mouse, tumor cells and non-transgenic of
different mice, we used the Significance Analysis of Microarrays
(SAM) algorithm (ArrayTrack), which contains a sliding scale for
false discovery rate (FDR) of significantly up- and down-regulated
genes [228]. All data were permuted 100 cycles by using the two
classes, unpaired data mode of the algorithm. As cut-off for
significance an estimated FDR of 0.001 was chosen. Moreover, a
cut-off for fold-change of differential expression of 2 was used. The
full description of the Extraction protocol, labeling and hybrid-
ization protocol and data processing is obtainable in the GEO
DATA base under http://www.ncbi.nlm.nih.gov/geo/ (accession
number GSE14277).
Principal component analysis (PCA) and hierarchical gene
cluster analysis (HCA)
Two clustering approaches were used to determine components
of variation in the data in this study as follows.
A) Principal-component analysis (PCA) that was used to obtain
a simplified visualization of entire datasets. PCA is a useful linear
approach to obtain a simplified visualization of entire datasets,
without losing experimental information (variance). PCA allowed
the dimension of complex data to be reduced and highlights the
most relevant features of a given dataset to be highlighted.
B) Hierarchical gene clustering (HCA) where the data points
were organized in a phylogenetic tree in which the branch lengths
represent the degree of similarity between the values. After
normalisation and SAM analysis a total of 3246 significant genes
were used for hierarchical clustering.
Functional analysis of the significant genes with IPA
Lists of significantly differentially expressed genes were
uploaded to Ingenuity Pathways Analysis (IPA, Ingenuity Systems
Inc., Redwood City, CA, USA) (www.Ingenuity.com) and
functional annotation and pathway analysis was performed. IPA
is a commercial, web-based interface that uses a variety of
computational algorithms to identify and establish cellular
networks that statistically fit the input gene list and expression
values from experiments. The analysis uses a database of gene
interactions culled from literature and updated every quarter of
the year.
Additionally, Venn diagrams were used to examine the overlap
of resulting lists of genes differentially expressed between the
different sample sets.
Quantitative real-time PCR
Corroboration of RNA expression data was performed by real-
time PCR using the ABI PRISM 7500 Sequence Detection System
Instrument (Applied Biosystems, Applera Deutschland GmbH,
Darmstadt, Germany). Total RNA (200 ng) underwent reverse
transcription using an Omniscript RT Kit (Qiagen, Santa Clarita,
CA, USA) according to the manufacturer’s instruction. PCR
reactions were performed according to the instructions of the
manufacturer using commercially available assays-on-demand
(Applied Biosystems, Applera Deutschland GmbH, Darmstadt,
Germany). CT values were calculated by the ABI PRISM software
and relative gene expression levels were expressed as the difference
in CT values of the target gene and the control gene Actin beta.
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Each tumor section (8 mm in thickness) was deparaffinized in
roti-histol for 2 times 8 minutes, these were dehydrogenated by
means of a descending alcohol row. The following incubation steps
were accomplished: 2 times 3 minutes in 96% ethanol, 2 times 2
minutes in 70% Ethanol, and 2 minutes in Aqua dest. The pre-
treated slices were heated in a autoclave for 15 min in citrate
buffer submitted of an antigen retrieval before the colouring first.
For blocking endogenous peroxidase activity the slices covered for
30 minutes with 3% hydrogen peroxide/Methanol peroxidase
blocking solution. After a wash step, the slices were incubated with
the primary polyclonal anti-body against Cldn2 (Biomol GmbH,
Germany), Mcc (Proteintech Group, Inc., IL, USA), S100a14
(Applied Biological Materials Inc. Richmond, BC Canada), Cdh5,
Fetub, Fst, Orm1, RasGRF1, Hnf4a and Reck (Santa Cruz, Santa
Cruz Biotechnologys Inc., CA, USA) for 45 minutes. After
washing, a streptavidin horseradish peroxidase detection kit
(Envision DAKO, Hamburg, Germany) containing 3,39-diamino-
benzidine solution as substrate was used for immunohistochemical
staining according to the manufacturer’s instructions. Harris
Ha ¨matoxylin was used as the counterstaining. The specificity of
the immunostaining was confirmed by positive and negative
control staining. For negative controls we used mouse nonimmune
immunoglobulin G or blocking peptide instead of the primary
antibody. For the positive control staining we use normal tissue
with known positive immunoreactions to the antibodies (Cldn2,
Fst, Mcc, S100a14=colon; Fetub, Orm1, Reck, RasGRF1,
Hnf4a=liver and Cdh5=heart).
Supporting Information
Figure S1 Ingenuity - Canonical Pathways: adenocarcinoma vs
transgenic. This figure shows the canonical pathways which were
overrepresented in the group of significantly regulated genes in
adenocarcinoma versus transgenic mice.
Found at: doi:10.1371/journal.pone.0007315.s001 (0.71 MB
DOC)
Figure S2 Ingenuity - Canonical Pathways: adenocarcinoma vs
non-transgenic. This figure shows the canonical pathways which
were overrepresented in the group of significantly regulated genes
in adenocarcinoma versus non-transgenic mice.
Found at: doi:10.1371/journal.pone.0007315.s002 (2.11 MB
DOC)
Figure S3 Corroboration by quantitative real-time PCR (Part I).
Real-time PCR curves of seven genes assessed by Taqman
technology as well as of the reference gene ACTB of a
representative experiment are shown. The differences of the Ct
values of target and ACTB (deltaCT) are indicated. The smaller
the deltaCT, the higher the relative expression level of the target
mRNA.
Found at: doi:10.1371/journal.pone.0007315.s003 (6.74 MB
DOC)
Figure S4 Corroboration by quantitative real-time PCR (Part
II). Real-time PCR curves of seven genes assessed by Taqman
technology as well as of the reference gene ACTB of a
representative experiment are shown. The differences of the Ct
values of target and ACTB (deltaCT) are indicated. The smaller
the deltaCT, the higher the relative expression level of the target
mRNA.
Found at: doi:10.1371/journal.pone.0007315.s004 (6.76 MB
DOC)
Figure S5 Gene networks exclusively regulated in dysplasia.
Ingenuity networks generated by mapping the focus genes that
were associated in dysplasia (descriptions see Fig. 6).
Found at: doi:10.1371/journal.pone.0007315.s005 (3.62 MB TIF)
Table S1 List of genes with changed expressions that are
significantly overexpressed in adenocarcinoma versus non-altered
transgenic mice: 473 significantly regulated genes. This table
shows the RefSeq transcript IDs, Unigene IDs, gene titles, gene
symbols, and fold changes of the significantly regulated genes.
Found at: doi:10.1371/journal.pone.0007315.s006 (0.65 MB
DOC)
Table S2 List of genes with changed expressions that are
significantly over- or under-expressed in adenocarcionam versus
non-transgenic mice: 541 significantly regulated genes. This table
shows the RefSeq transcript IDs, Unigene IDs, gene titles, gene
symbols, and fold changes of the significantly regulated genes.
Found at: doi:10.1371/journal.pone.0007315.s007 (0.74 MB
DOC)
Table S3 List of genes with changed expressions that are
significantly over- or under-expressed in unaltered transgenic
versus non-transgenic mice: 18 significantly regulated genes. This
table shows the RefSeq transcript IDs, Unigene IDs, gene titles,
gene symbols, and fold changes of the significantly regulated
genes.
Found at: doi:10.1371/journal.pone.0007315.s008 (0.05 MB
DOC)
Text S1 Description of gene regulated networks associated in
dysplasia.
Found at: doi:10.1371/journal.pone.0007315.s009 (0.04 MB
DOC)
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